<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00978653</url>
  </required_header>
  <id_info>
    <org_study_id>200931386</org_study_id>
    <nct_id>NCT00978653</nct_id>
  </id_info>
  <brief_title>The Effect of Uric Acid Decrement on Endothelial Function in Patients With Chronic Renal Failure</brief_title>
  <official_title>Prospective Study of Allopurinol Treatment That Improves Endothelial Function by Decreasing Uric Acid Levels of Patients With Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this prospective study, the investigators aimed to evaluate the effects of improved
      hyperuricemia, a minor cardiovascular risk factor, on endothelial dysfunction in patients
      with chronic kidney disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endothelial dysfunction (ED) is a key event in the development of atherosclerotic
      cardiovascular disease observed in patients with chronic kidney disease (CKD). Experimental
      models have shown that hyperuricemia causes hypertension and renin angiotensin system
      activation. In this prospective study, the investigators aimed to evaluate the effects of
      improved hyperuricemia, a minor cardiovascular risk factor, on ED in patients with CKD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial function improvement with uric acid lowering treatment</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hyperuricemia</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Allopurinol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hyperuricemic (uric acid (UA)&gt;7 mg/dL), nondiabetic CKD patients without any comorbidity, age&lt;60 years with creatinine clearance (CrCl) between 20 and 60ml/min were evaluated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>allopurinol</intervention_name>
    <description>150 mg once a day</description>
    <arm_group_label>Allopurinol</arm_group_label>
    <other_name>urikoliz</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Laboratory finding of hyperuricemia

          -  Patients between ages of 18 and 60 years

          -  Non-diabetic patients

          -  Creatinine clearance values between 20 and 60 mL/min/1.73 m2

        Exclusion Criteria:

          -  Low (&lt; 20 ml/min/1.73 m2) creatinine clearance,

          -  Patients with diabetes mellitus, ischemic heart disease, acute coronary syndrome,
             congestive heart failure (CHF) (New York Heart Association class II or greater),
             valvular heart disease and a history of cerebral infarction or transient ischemic
             attack.

          -  Patients taking urate lowering medication (allopurinol and probenecid)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Berna Yelken, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Nephrology, Istanbul Faculty of Medicine, Istanbul University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yasar Caliskan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Nephrology, Istanbul Faculty of Medicine, Istanbul University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alaattin Yildiz, Prof, MD</last_name>
    <role>Study Director</role>
    <affiliation>Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Numan Gorgulu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine, Istanbul University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Istanbul Faculty of Medicine</name>
      <address>
        <city>Istanbul</city>
        <zip>34390</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2009</study_first_submitted>
  <study_first_submitted_qc>September 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 17, 2009</study_first_posted>
  <last_update_submitted>September 21, 2009</last_update_submitted>
  <last_update_submitted_qc>September 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2009</last_update_posted>
  <responsible_party>
    <name_title>Alaattin Yildiz</name_title>
    <organization>Division of Nephrology, Department of Internal Medicine, Istanbul Faculty of Medicine</organization>
  </responsible_party>
  <keyword>allopurinol</keyword>
  <keyword>chronic kidney disease</keyword>
  <keyword>endothelial dysfunction</keyword>
  <keyword>hyperuricemia</keyword>
  <keyword>uric acid</keyword>
  <keyword>vascular endothelium</keyword>
  <keyword>xanthine oxidase inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Uric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

